Image credit: Adobe
NeoGenomics, Inc., a leading provider of oncology testing and global contract research services headquartered in the US, has recently announced plans to open a state-of-the-art research laboratory in China in association with the new lab PPD, Inc. is opening in Suzhou.
The NeoGenomics laboratory is expected to support Greater China-focused clinical trials and testing for global and local Chinese pharmaceutical companies. Based in Suzhou New District, Jiangsu Province, the NeoGenomics research facility will be operational in 2021. NeoGenomics will offer pharma research services, including early translational and clinical research trial studies supporting global pharmaceutical initiatives.
In a very similar arrangement to the laboratory opened in Singapore in 2019, NeoGenomics will establish services in the same building as PPD. This continues the multi-year alliance between the two companies and highlights the complementarity of technologies and service offerings of both organizations.
